Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
Pathophysiology of Diabetes01:20

Pathophysiology of Diabetes

Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility, suggesting a...
Ovarian Cycle01:27

Ovarian Cycle

The menstrual cycle includes a critical component known as the ovarian cycle, which undergoes two main phases each month—the follicular phase and the luteal phase. The follicular phase is variable and averaging around 14 days. Ovulation, triggered by a surge in luteinizing hormone (LH), marks the transition between the two phases. The second phase, the luteal phase, is relatively consistent, lasting approximately 14 days, and is marked by the activity of the corpus luteum. While a cycle length...
Disorders of the Female Reproductive System01:24

Disorders of the Female Reproductive System

The female reproductive system can be affected by several disorders, including Premenstrual Syndrome (PMS), Premenstrual Dysphoric Disorder (PMDD), endometriosis, and various forms of cancer. PMS and PMDD are cyclical conditions that cause physical and emotional distress, with symptoms that include edema, mood swings, and food cravings. PMDD is a more severe form of PMS characterized by increased symptom severity that peaks during the luteal phase and tends to improve or resolve shortly after...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction to: Autocrine activation of JAK2 by IL-11 promotes platinum drug resistance.

Oncogene·2026
Same author

Retraction Note: miR-137 mediates the functional link between c-Myc and EZH2 that regulates cisplatin resistance in ovarian cancer.

Oncogene·2026
Same author

Incidence, risk factors, and clinical outcomes of peripartum cardiomyopathy in Hong Kong.

Hong Kong medical journal = Xianggang yi xue za zhi·2025
Same author

SOAT1 in ovarian cancer cells regulates immune response mediated by CD8<sup>+</sup> T cells.

Journal of ovarian research·2025
Same author

Diagnosis and management of gestational trophoblastic disease: 2025 update.

International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics·2025
Same author

Dichorionic twin pregnancy with selective fetal growth restriction: prognosis, complications and implications of Doppler abnormalities.

Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology·2025
Same journal

A risk-based classification of late-onset fetal growth disorders according to intrapartum fetal compromise.

Best practice & research. Clinical obstetrics & gynaecology·2026
Same journal

The Cardiac-Fetal-Placental Unit: links between umbilical venous flow and maternal hemodynamics in fetal growth restriction.

Best practice & research. Clinical obstetrics & gynaecology·2026
Same journal

Psychosocial interventions for women who are pregnant following a previous reproductive loss: A scoping review.

Best practice & research. Clinical obstetrics & gynaecology·2026
Same journal

Controversies in fetal therapy.

Best practice & research. Clinical obstetrics & gynaecology·2026
Same journal

Alloimmunisation in pregnancy: current management and future perspectives.

Best practice & research. Clinical obstetrics & gynaecology·2026
Same journal

Consensus in prenatal management of Hemolytic disease of the fetus and newborn.

Best practice & research. Clinical obstetrics & gynaecology·2026
See all related articles

Related Experiment Video

Updated: May 25, 2026

Isolation of Primary Mouse Trophoblast Cells and Trophoblast Invasion Assay
10:28

Isolation of Primary Mouse Trophoblast Cells and Trophoblast Invasion Assay

Published on: January 8, 2012

Gestational trophoblastic disease.

K Y Tse1, Hextan Y S Ngan

  • 1Department of Obstetrics and Gynaecology, Queen Mary Hospital, the University of Hong Kong, Hong Kong. tseky@hkucc.hku.hk

Best Practice & Research. Clinical Obstetrics & Gynaecology
|January 31, 2012
PubMed
Summary
This summary is machine-generated.

Gestational trophoblastic disease (GTD) is treatable, with most women maintaining fertility. Subsequent pregnancies after molar pregnancy or GTD treatment generally have favorable outcomes, though a waiting period is advised.

More Related Videos

Transcriptional Analysis by Nascent RNA FISH of In Vivo Trophoblast Giant Cells or In Vitro Short-term Cultures of Ectoplacental Cone Explants
08:26

Transcriptional Analysis by Nascent RNA FISH of In Vivo Trophoblast Giant Cells or In Vitro Short-term Cultures of Ectoplacental Cone Explants

Published on: August 31, 2016

Related Experiment Videos

Last Updated: May 25, 2026

Isolation of Primary Mouse Trophoblast Cells and Trophoblast Invasion Assay
10:28

Isolation of Primary Mouse Trophoblast Cells and Trophoblast Invasion Assay

Published on: January 8, 2012

Transcriptional Analysis by Nascent RNA FISH of In Vivo Trophoblast Giant Cells or In Vitro Short-term Cultures of Ectoplacental Cone Explants
08:26

Transcriptional Analysis by Nascent RNA FISH of In Vivo Trophoblast Giant Cells or In Vitro Short-term Cultures of Ectoplacental Cone Explants

Published on: August 31, 2016

Area of Science:

  • Gynecology
  • Reproductive Endocrinology
  • Oncology

Background:

  • Gestational trophoblastic disease (GTD) affects women of reproductive age.
  • GTD is highly treatable with a favorable prognosis.
  • Fertility preservation is a key concern for affected women.

Purpose of the Study:

  • To review the impact of GTD and its treatments on future fertility.
  • To discuss pregnancy outcomes after GTD.
  • To highlight the importance of patient counseling and multidisciplinary care.

Main Methods:

  • Literature review of studies on GTD, fertility, and pregnancy outcomes.
  • Analysis of data regarding chemotherapy effects and fertility-sparing treatments.
  • Synthesis of recommendations for pregnancy intervals and contraception.

Main Results:

  • Uterine evacuation for hydatidiform mole has minimal impact on future fertility.
  • Subsequent pregnancy outcomes are comparable to the general population, with a slightly increased risk of recurrence.
  • Chemotherapy for persistent GTD has a >70% live birth rate with no increased fetal abnormality risk.
  • Successful pregnancies are reported after choriocarcinoma and fertility-sparing treatments for placental-site trophoblastic tumors.

Conclusions:

  • Most women with GTD can achieve successful future pregnancies.
  • Adherence to recommended pregnancy intervals post-treatment is crucial.
  • Psychological and sexual support, alongside multidisciplinary care, is essential for GTD survivors.